GW&K Investment Management LLC Trims Holdings in Balchem Co. (NASDAQ:BCPC)

GW&K Investment Management LLC reduced its stake in shares of Balchem Co. (NASDAQ:BCPCGet Rating) by 21.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 276,819 shares of the basic materials company’s stock after selling 77,324 shares during the period. GW&K Investment Management LLC owned 0.85% of Balchem worth $46,671,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the company. Wasatch Advisors Inc. lifted its holdings in shares of Balchem by 10.7% during the 3rd quarter. Wasatch Advisors Inc. now owns 1,828,385 shares of the basic materials company’s stock worth $265,244,000 after acquiring an additional 176,500 shares during the period. Conestoga Capital Advisors LLC lifted its holdings in shares of Balchem by 0.4% during the 4th quarter. Conestoga Capital Advisors LLC now owns 1,000,708 shares of the basic materials company’s stock worth $168,719,000 after acquiring an additional 3,657 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Balchem by 8.1% during the 4th quarter. Geode Capital Management LLC now owns 603,823 shares of the basic materials company’s stock worth $101,804,000 after acquiring an additional 45,326 shares during the period. Bank of New York Mellon Corp increased its position in Balchem by 0.7% during the 3rd quarter. Bank of New York Mellon Corp now owns 363,740 shares of the basic materials company’s stock worth $52,767,000 after purchasing an additional 2,536 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in Balchem by 1.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 264,911 shares of the basic materials company’s stock worth $44,665,000 after purchasing an additional 3,191 shares in the last quarter. Institutional investors and hedge funds own 89.60% of the company’s stock.

Balchem stock traded up $1.82 during midday trading on Friday, reaching $120.52. 153,100 shares of the stock traded hands, compared to its average volume of 101,494. The firm has a fifty day moving average price of $130.19 and a two-hundred day moving average price of $145.74. The firm has a market cap of $3.87 billion, a price-to-earnings ratio of 38.63 and a beta of 0.66. Balchem Co. has a fifty-two week low of $114.79 and a fifty-two week high of $174.29. The company has a current ratio of 2.59, a quick ratio of 1.71 and a debt-to-equity ratio of 0.17.

Balchem (NASDAQ:BCPCGet Rating) last released its earnings results on Friday, April 29th. The basic materials company reported $0.89 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.16. Balchem had a net margin of 12.07% and a return on equity of 13.02%. The business had revenue of $228.87 million for the quarter, compared to the consensus estimate of $211.00 million. During the same period in the previous year, the firm earned $0.87 EPS. Analysts anticipate that Balchem Co. will post 3.46 earnings per share for the current year.

A number of analysts recently issued reports on BCPC shares. Zacks Investment Research raised shares of Balchem from a “hold” rating to a “buy” rating and set a $133.00 target price for the company in a research report on Wednesday, May 11th. HC Wainwright lowered their price objective on shares of Balchem from $155.00 to $152.00 and set a “buy” rating for the company in a research report on Monday, May 2nd. Sidoti raised shares of Balchem from a “neutral” rating to a “buy” rating and set a $175.00 price objective for the company in a research report on Tuesday, February 22nd. Finally, StockNews.com assumed coverage on shares of Balchem in a research report on Thursday, March 31st. They issued a “buy” rating for the company. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, Balchem presently has an average rating of “Buy” and a consensus target price of $151.25.

Balchem Profile (Get Rating)

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets in the United States and internationally. It operates through three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products.

Featured Stories

Institutional Ownership by Quarter for Balchem (NASDAQ:BCPC)

Receive News & Ratings for Balchem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Balchem and related companies with MarketBeat.com's FREE daily email newsletter.